Ion Exchange (India) Limited has released its Q1 FY27 financial results, reporting a consolidated operating income of ₹7,005 Mn. The company also highlighted key performance indicators across its business segments, including Treatment Solutions, Industrial Products, Lifecycle Services, Specialty Chemicals, and Consumer Products. Future growth drivers and strategic initiatives were also outlined, offering insights into the company’s outlook.
Ion Exchange Reports Strong Q1 FY27 Financial Performance
Ion Exchange (India) Limited has officially announced its financial results for the first quarter of the fiscal year 2026-27 (Q1 FY27). The company showcased a robust performance across its consolidated operations, with a reported Operating Income of ₹7,005 Mn. This represents a significant increase, reflecting the company’s strategic growth initiatives and market positioning.
Key Financial Highlights (Q1-FY27)
The consolidated performance for Q1-FY27 reveals an Operating EBITDA of ₹318 Mn, with Operating EBITDA Margins standing at 4.54%. The Net Profit for the quarter was ₹31 Mn, resulting in PAT Margins of 0.44% and a Diluted EPS of ₹0.35. These figures provide a snapshot of the company’s profitability and operational efficiency during the period.
Standalone performance also saw an Operating Income of ₹6,356 Mn, with Operating EBITDA at ₹307 Mn and Operating EBITDA Margins at 4.83%. The Net Profit stood at ₹114 Mn, with PAT Margins at 1.79% and Diluted EPS at ₹0.93. The substantial difference between consolidated and standalone figures underscores the contribution of subsidiaries and associate companies.
Order Book and Pipeline Strength
As of June 30, 2026, the company’s Total Orderbook was valued at ₹24,730 Mn, with an impressive Bid Pipeline of ₹97,770 Mn. This substantial pipeline, including Engineering projects of ₹21,820 Mn and Outstanding UP SWSM at ₹2,810 Mn, indicates strong future revenue visibility and growth potential.
Segmental Performance Insights
The presentation further breaks down performance by key segments:
- Treatment Solutions: Revenue growth of 14% with dispatches resuming, though margins are impacted by legacy projects. Future growth drivers include backlog liquidation and overseas opportunities.
- Industrial Products: Revenue growth of 14% and a significant increase in EBIT% from 5.53% to 11.89%, driven by strong performance in water treatment solutions and membranes. Expansion and geographical reach are key future drivers.
- Lifecycle Services: Revenue growth of 28% with EBIT% at 9.92% due to input costs. Focus remains on O&M, consumables, and expanding digital solutions.
- Specialty Chemicals: Revenue growth of 21%, despite EBIT being down due to geopolitical impact and higher costs from facility capex. Future growth hinges on offtake from the Roha Plant and pharma resins.
- Consumer Products: Revenue growth of 33%, with EBIT slightly up. Strong growth across product lines is expected to continue, driven by the softener market and wellness products.
Historical Financial Overview
The document also provides a historical perspective, detailing standalone and consolidated financial performance from FY23 to FY26, along with balance sheet data. This historical data allows for a comprehensive understanding of the company’s financial trajectory and strategic decisions over the past few years.
Source: BSE
